Premium peptide catalog built for advanced laboratory workflows.
RT50
Mechanism of action Retatrutide (LY3437943) is a triple agonist simultaneously activating GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon (GCGR) receptors. The GLP-1 component reduces appetite and increases satiety via gastric emptying and the hypothalamus; GIP improves insulin sensitivity and fat distribution; glucagon increases energy expenditure through thermogenesis and promotes lipolysis. This multi-receptor approach is studied for superior synergistic potential versus single or dual agonists. Research applications • Energy metabolism and body composition • GLP-1, GIP and glucagon pathways in weight regulation • Insulin sensitivity and adipose tissue distribution • Thermogenesis and lipolysis Biological properties studied • Triple GLP-1R, GIPR, GCGR agonism • Potentially superior metabolic efficacy vs simple/dual agonists • Modulation of visceral vs subcutaneous fat • Purity: ≥99% (HPLC) • Presentation: Lyophilized powder 50 mg • Storage: 2-8°C • Recommended diluent: Bacteriostatic water (BA) Research use only.
220,00 €
RT20
Mechanism of action Retatrutide (LY3437943) is a triple agonist simultaneously activating GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon (GCGR) receptors. The GLP-1 component reduces appetite and increases satiety via gastric emptying and the hypothalamus; GIP improves insulin sensitivity and fat distribution; glucagon increases energy expenditure through thermogenesis and promotes lipolysis. This multi-receptor approach is studied for superior synergistic potential versus single or dual agonists. Research applications • Energy metabolism and body composition • GLP-1, GIP and glucagon pathways in weight regulation • Insulin sensitivity and adipose tissue distribution • Thermogenesis and lipolysis Biological properties studied • Triple GLP-1R, GIPR, GCGR agonism • Potentially superior metabolic efficacy vs simple/dual agonists • Modulation of visceral vs subcutaneous fat • Purity: ≥99% (HPLC) • Presentation: Lyophilized powder 20 mg • Storage: 2-8°C • Recommended diluent: Bacteriostatic water (BA) Research use only.
130,00 €
RT10
Mechanism of action Retatrutide (LY3437943) is a triple agonist simultaneously activating GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon (GCGR) receptors. The GLP-1 component reduces appetite and increases satiety via gastric emptying and the hypothalamus; GIP improves insulin sensitivity and fat distribution; glucagon increases energy expenditure through thermogenesis and promotes lipolysis. This multi-receptor approach is studied for superior synergistic potential versus single or dual agonists. Research applications • Energy metabolism and body composition • GLP-1, GIP and glucagon pathways in weight regulation • Insulin sensitivity and adipose tissue distribution • Thermogenesis and lipolysis Biological properties studied • Triple GLP-1R, GIPR, GCGR agonism • Potentially superior metabolic efficacy vs simple/dual agonists • Modulation of visceral vs subcutaneous fat • Purity: ≥99% (HPLC) • Presentation: Lyophilized powder 10 mg • Storage: 2-8°C • Recommended diluent: Bacteriostatic water (BA) Research use only.
95,00 €
RT5
Mechanism of action Retatrutide (LY3437943) is a triple agonist simultaneously activating GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon (GCGR) receptors. The GLP-1 component reduces appetite and increases satiety via gastric emptying and the hypothalamus; GIP improves insulin sensitivity and fat distribution; glucagon increases energy expenditure through thermogenesis and promotes lipolysis. This multi-receptor approach is studied for superior synergistic potential versus single or dual agonists. Research applications • Energy metabolism and body composition • GLP-1, GIP and glucagon pathways in weight regulation • Insulin sensitivity and adipose tissue distribution • Thermogenesis and lipolysis Biological properties studied • Triple GLP-1R, GIPR, GCGR agonism • Potentially superior metabolic efficacy vs simple/dual agonists • Modulation of visceral vs subcutaneous fat • Purity: ≥99% (HPLC) • Presentation: Lyophilized powder • Storage: 2-8°C • Recommended diluent: Bacteriostatic water (BA) Research use only.
70,00 €
SM30
Mechanism of action Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) analogue with extended half-life through structural modification and albumin binding. As a GLP-1R agonist, it exerts central effects (appetite regulation, satiety, energy centres) and peripheral effects: stimulation of glucose-dependent insulin secretion, glucagon inhibition, delayed gastric emptying. Research also explores its effects on lipid metabolism and adipose tissue distribution. Research applications • Glucose metabolism and glycemic control (HbA1c) • Appetite regulation and satiety mechanisms • Body composition and energy metabolism • Adipose tissue inflammation and ectopic lipid deposition Biological properties studied • Central and peripheral GLP-1R agonism • Improved insulin sensitivity • Reduction of triglycerides and LDL cholesterol • Extended half-life allowing weekly administration • Purity: ≥99% (HPLC) • Presentation: Lyophilized powder 30 mg • Storage: 2-8°C • Recommended diluent: Bacteriostatic water (BA) • Reconstituted solution storage: ~21 days refrigerated (2-8°C) Research use only.
109,00 €
SM20
Mechanism of action Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) analogue with extended half-life through structural modification and albumin binding. As a GLP-1R agonist, it exerts central effects (appetite regulation, satiety, energy centres) and peripheral effects: stimulation of glucose-dependent insulin secretion, glucagon inhibition, delayed gastric emptying. Research also explores its effects on lipid metabolism and adipose tissue distribution. Research applications • Glucose metabolism and glycemic control (HbA1c) • Appetite regulation and satiety mechanisms • Body composition and energy metabolism • Adipose tissue inflammation and ectopic lipid deposition Biological properties studied • Central and peripheral GLP-1R agonism • Improved insulin sensitivity • Reduction of triglycerides and LDL cholesterol • Extended half-life allowing weekly administration • Purity: ≥99% (HPLC) • Presentation: Lyophilized powder 20 mg • Storage: 2-8°C • Recommended diluent: Bacteriostatic water (BA) • Reconstituted solution storage: ~21 days refrigerated (2-8°C) Research use only.
80,00 €
SM15
Mechanism of action Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) analogue with extended half-life through structural modification and albumin binding. As a GLP-1R agonist, it exerts central effects (appetite regulation, satiety, energy centres) and peripheral effects: stimulation of glucose-dependent insulin secretion, glucagon inhibition, delayed gastric emptying. Research also explores its effects on lipid metabolism and adipose tissue distribution. Research applications • Glucose metabolism and glycemic control (HbA1c) • Appetite regulation and satiety mechanisms • Body composition and energy metabolism • Adipose tissue inflammation and ectopic lipid deposition Biological properties studied • Central and peripheral GLP-1R agonism • Improved insulin sensitivity • Reduction of triglycerides and LDL cholesterol • Extended half-life allowing weekly administration • Purity: ≥99% (HPLC) • Presentation: Lyophilized powder 15 mg • Storage: 2-8°C • Recommended diluent: Bacteriostatic water (BA) • Reconstituted solution storage: ~21 days refrigerated (2-8°C) Research use only.
60,00 €
SM10
Mechanism of action Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) analogue with extended half-life through structural modification and albumin binding. As a GLP-1R agonist, it exerts central effects (appetite regulation, satiety, energy centres) and peripheral effects: stimulation of glucose-dependent insulin secretion, glucagon inhibition, delayed gastric emptying. Research also explores its effects on lipid metabolism and adipose tissue distribution. Research applications • Glucose metabolism and glycemic control (HbA1c) • Appetite regulation and satiety mechanisms • Body composition and energy metabolism • Adipose tissue inflammation and ectopic lipid deposition Biological properties studied • Central and peripheral GLP-1R agonism • Improved insulin sensitivity • Reduction of triglycerides and LDL cholesterol • Extended half-life allowing weekly administration • Purity: ≥99% (HPLC) • Presentation: Lyophilized powder • Storage: 2-8°C • Recommended diluent: Bacteriostatic water (BA) • Reconstituted solution storage: ~21 days refrigerated (2-8°C) Research use only.
50,00 €
